Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Charles River Laboratories and AstraZeneca Renew Strategic Partnership Agreement
July 30, 2015 7:01 AM EDT- Leading Global CRO and Global Biopharmaceutical Company Extend Relationship to Accelerate Drug Development -
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has extended its initial three-year partnership with AstraZeneca (NYSE: AZN) for an additional five-year period. Under the agreement, which extends into 2020, Charles River retains its position as AstraZenecas preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).
James C. Foster, Chairman,... More
Charles River Laboratories Announces Second-Quarter 2015 Results from Continuing Operations
July 30, 2015 7:00 AM EDTSecond-Quarter Revenue of $339.6 Million
Second-Quarter GAAP Earnings per Share of $1.02
and
Non-GAAP Earnings per Share of $0.96
Updates 2015 Guidance for Celsis Acquisition
Renews Strategic Partnership with AstraZeneca
Plans to Reopen Shrewsbury, Massachusetts Facility in Early 2016
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2015. For the quarter, revenue from continuing operations was $339.6 million, a decrease of 0.5% from $341.2 million in the second quarter of 2014. Foreign currency... More
